SL Science presents glioblastoma cell therapy data at WCP 2026
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
SL Science Announces Successful Exhibition of Breakthrough Brain Cancer Therapy Research at the 2026 World Congress of Basic and Clinical Pharmacology
July 17, 2026 8:00 AM EDTJoint presentation with Taipei Medical University, JY BioMed, and HeXun Biosciences highlighted the power of gamma delta () T cells in eliminating glioblastoma in preclinical studies.
TAIPEI, TAIWAN, July 17, 2026 (GLOBE NEWSWIRE) -- SL Science Holding Limited (NASDAQ: SLBT) ("SL Science" or the "Company"), a biotechnology company developing next-generation immune cell therapies, today announced its successful exhibition and participation at the 2026 World Congress of Basic and Clinical Pharmacology (WCP 2026) held at July 12-17, 2026 in Melbourne, Australia. Together with its esteemed academic and industry partners, the Company presented highly... More
